PRNewsWire
22 Oct 2026, 10:46 UTC · 1h ago
Impact · against what's priced in
Quest Diagnostics (DGX) shares are likely to rise following an upward revision of full-year revenue and EPS guidance. Strong organic volume growth is effectively offsetting pricing pressure, signaling robust demand and operational efficiency through AI and automation.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish · 5 new · 0 priced in
Quest Diagnostics raised its full year 2026 adjusted diluted EPS guidance to a range of $11.25 to $11.35 from $11.05 to $11.25.
Newpress release dated Oct 22, 2026
So whatThis upward revision raises the bottom-end estimate by $0.20 per share for the full year.
More positive than 94% of claims this week
Quest Diagnostics raised its full year 2026 net revenue guidance to a range of $12.065 billion to $12.105 billion from $11.95 billion to $12.05 billion.
Continue reading
5 related stories
The company raised its full-year adjusted EPS guidance to $11.25-$11.35 (from $11.05-$11.25) and revenue guidance to $12.065B-$12.105B (from $11.95B-$12.05B), driven by a 14.5% increase in Q3 requisition volume.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Newpress release dated Oct 22, 2026
So whatThe new guidance implies a minimum revenue growth of 9.3% for the year, up from the previous 8.3% floor.
More positive than 88% of claims this week
Third quarter 2026 adjusted diluted EPS grew 15.4% year-over-year to $3.00.
Newpress release dated Oct 22, 2026
So whatThe adjusted EPS beat the previous year's $2.60 by $0.40 per share in a single quarter.
More positive than 80% of claims this week
Requisition volume increased by 14.5% in the third quarter of 2026, while revenue per requisition fell by 4.2%.
Newpress release dated Oct 22, 2026
So whatThe volume growth is offsetting pricing pressure, with the volume increase (~14%) significantly outweighing the price decline (~4%).
More positive than 67% of claims this week
The company will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange.
Newpress release dated Oct 22, 2026
So whatThis provides a specific date for potential long-term strategic updates in Q1 2027.
More positive than 46% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported strong revenue and EPS growth, and raised its full-year financial guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
36m ago
—
DGX hasn't traded since this ran. Last close $238.68 (Oct 21); the reaction starts at the next open.
DGX chart →
